Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
May 2016
April 2016
-
Media ReleaseNovartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumorsIf approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional…
-
Collaborating to unlock secrets of the microbiome
Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.
-
Media ReleaseNovartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever SyndromesSubject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…
-
Patient advocacy at work: one man’s contributions to the COPD community
Read how one caregiver established an association to provide resources for both COPD patients and caregivers.
-
Talking to: Bruno Strigini on why we're entering a transformative time in cancer care
Accelerating Research to Get Answers Faster
-
Media ReleaseNovartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growthNet sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
-
Media ReleaseNovartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen WachstumsDer Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34%…
-
Media ReleaseNovartis a enregistré un premier trimestre solide, malgré la perte d'exclusivité de Gleevec, et investi dans de nouveaux lancements pour soutenir la croissance à long termeChiffre d'affaires net en hausse de 1% (tcc[1]), les produits de croissance ayant compensé l'impact du générique de Gleevec Les produits de croissance[2] ont progressé de 24% (en USD) à USD 3,9…
-
Media ReleaseNovartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complexEverolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most…
-
Factory foreman keeps liver’s line workers on task
A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.
Pagination
- ‹ Previous page
- 1
- …
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- …
- 152
- › Next page